Obesity

GLP 1 therapies have redefined what obesity pharmacotherapy can achieve, but efficacy is no longer the only battleground.

What Patients Need Next and Who Will Deliver It

New global syndicated survey highlights a striking contradiction at the heart of how obesity is understood, especially by those living with it.

New 14-country study from Ipsos reveals self-blame, outdated narratives and a hidden daily toll.

Despite media discussions around the drugs, only around a third across 30 countries have heard about the drugs, with a lot of the discourse taking place via social media according to the Ipsos Health Service Report.

Ipsos’ latest AI-powered innovation offers unparalleled insights into the fast-moving consumer obesity treatment market – while reinforcing Ipsos’ position at the forefront of AI applications in market research.

Our evolutionary tale began 6 million years ago, when humans were programmed to hoard calories in a world of scarcity. Today, that ancient wiring has become our greatest health risk.

Security, Inflation, Perils of Perception … Ipsos Update explores the latest and research & thinking on key topics from Ipsos teams around the world.

One of this century’s biggest game-changers will likely be a novel drug class that’s showing unprecedented success, or the promise of it, in treating some of the world’s most prevalent conditions.